Blinatumomab nonresponse correlates with poor survival after brexucabtagene autoleucel in B-cell ALL.

Srinagesh HK, Gupta V, Zhang A, Grunwald M, Connor M, Kota VK, Boccucci J, Ulrickson M, Pradeep R, Hill L, Tsai SB, O'Connor T, Sandhu K, Advani AS, Reshef R, Gordillo CA, Luskin MR, Chen EC, Lin C, Cassaday RD, Kopmar NE, Majhail NS, Battiwalla M, Strickland SA, Lee CJ, Bobillo SO, Hilal T, Park JH, Valtis YK, Faramand R, Solh MM, Guzowski C, Vasu S, Leonard JT, Tan V, Wang ES, McCauley R, Sasine J, Tang K, Miller K, Sutherland KC, Daunov M, Mohty R, Jamy O, Kumaran MV, Hoeg RT, Dykes KC, Logan AC, Othman T, Stock W, Schwartz M, Byrd K, Yalniz F, Bachanova V, Tracy S, Yaghmour G, Irizarry Gatell VM, Jackson CW, Oluwole OO, Dholaria B, O'Dwyer KM, Moore J, Roloff GW, Frey NV, Aldoss I, Shah BD, Oliai CH, Muffly LS